Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (NCT05126277)
A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).
🩺 Plain-English Summary (8th-Grade Level)
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Who can join: Review the eligibility criteria below.
Location: University Of Alabama — Birmingham, Alabama
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (147 Sites)
Showing the first 25 of 147 sites.
- University Of Alabama — Birmingham, Alabama
- Advanced Medical Research — La Palma, California
- University of California Irvine — Orange, California
- School Of Medicine — Sacromento, California
- University of California San Diego — San Deigo, California
- Kaiser Permanente — San Diego, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- University Of Miami — Miami, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Fides Clinical Research — Atlanta, Georgia
- Parris and Associates Rheumatology — Lawrenceville, Georgia
- Accurate Clinical Research — Lake Charles, Louisiana
- UMC New Orleans — New Orleans, Louisiana
- Wayne State University — Detroit, Michigan
- Univ of Nevada School of Med — Las Vegas, Nevada
- NY Nephrology — Clifton Park, New York
- Hospital for Special Surgery — New York, New York
- Northwell Health — New York, New York
- Circuit Clinical — Orchard Park, New York
- University Of Cincinnati — Cincinnati, Ohio
- Univ of Pennsylvania Medical Center — Philadelphia, Pennsylvania
- Precision Comprehensive Research — Colleyville, Texas
- Univof Texas Southwestern Med Cntr — Dallas, Texas
- Uni of Texas Health Science Center — San Antonio, Texas
- Uni Wisconsin School Med Pub Health — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Nephritis
- KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis — Palo Alto, California
- Daratumumab to Treat Active Lupus Nephritis — Rochester, Minnesota
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis — Birmingham, Alabama
- Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis — Glendale, Arizona
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases — Phoenix, Arizona
Explore by condition: All Lupus Nephritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.